MRK
NYSE · Pharmaceuticals
Merck & Co. Inc.
$146.87
-0.28 (-0.19%)
MRK News30 articles
Pfizer Stock Hits 52-Week High at 10x Forward Earnings
Pfizer shares climbed 1.7% to $29.04, hitting a 52-week high, as the stock trades at 10x projected 2026 earnings, with a 5.9% dividend yield.
Moderna Jumps 10% as Cancer Vaccine Trial Hits Key Goals
Moderna shares surged 9.93% after its cancer vaccine intismeran met two Phase 3 endpoints, adding $5.6B in market value. Full efficacy data remain undisclosed.
SCHD Rally Cuts Yield to 3.12%, Valuation Gap Persists
SCHD's strong 2026 rally has trimmed its yield to 3.12%, but its portfolio still trades at a discount to DGRO, maintaining its value appeal.
Moderna Slides 3.4% as $55B Valuation Faces Cancer Vaccine Commercial Test
Moderna (MRNA) dropped 3.4% Friday, but the stock is still up 130% on melanoma vaccine hopes. Analysts see $1B in sales by 2030, yet commercial hurdles and trial setbacks persist.
Moderna Soars 14% on Cancer Vaccine Optimism, Adds $8B in Value
Moderna's stock surged 14.4% after a Wolfe Research upgrade, adding $8 billion in market value. The rally follows promising melanoma vaccine results, but analysts caution on profitability.
Moderna Surges 12% as Wolfe Drops Bearish Stance on Cancer Vaccine
Moderna shares surged 12% after Wolfe Research upgraded the stock, citing a clearer approval path and $9.2 billion peak sales potential for its cancer vaccine intismeran.
SCHD ETF Nears Record High as $17.7B Inflows Reshape Dividend Strategy
The Schwab U.S. Dividend Equity ETF (SCHD) is near record highs, driven by $17.7B inflows, prompting investors to consider pairing it with growth ETFs.
Moderna's Cancer Vaccine Rally Outpaces Wall Street Targets
Moderna's stock soared 129% in a week on positive cancer vaccine data, leaving analyst targets far behind. The average price target is 45.7% below the current price.
Moderna's $28B Surge: Melanoma Trial Sparks Investor Frenzy
Moderna's market cap jumped $28B after a successful Phase 3 melanoma vaccine trial, but shares remain far above analyst targets.
MRK Surges 13% on Cancer Vaccine Data, Market Cap Jumps $44B
Merck (MRK) shares soared 13.3% to $153.12 after promising Phase 3 data for its melanoma vaccine with Moderna (MRNA), boosting market cap by $44.4B.
S&P 500 Recovers Most of Tuesday's Loss, Healthcare Leads as Tech Lags
The S&P 500 bounced back on Wednesday, recovering most of Tuesday's decline, but leadership shifted to healthcare as technology remained flat.
Salesforce Stock Surges 4.9% on JPMorgan's Bullish $250 Target
Salesforce (CRM) climbed 4.9% to $205.65 after JPMorgan set a $250 price target, implying 22% upside. The rally highlights optimism, but fiscal 2027 organic growth and margin targets remain a key focus.
XLV Retreats from Record as Mid-Sized Health Care Names Lag
XLV hit a record $169.71 before closing lower, lagging the S&P 500 by 0.74 points. Weakness among smaller health care holdings offset gains in top components.
Merck Stock Rises on MMR Split Order, but Revenue Gains Remain Distant
Merck (MRK) shares rose 1.89% after a presidential order to develop separate measles, mumps, and rubella vaccines, but analysts note the process could take over a decade and won't boost near-term revenue.
Pfizer Stock Surges 7% on Q2 Beat, Offering 6.4% Dividend Yield
Pfizer shares gained 7% last week, beating the S&P 500, after Q2 adjusted EPS topped consensus by 13.2%. The stock's 6.43% yield exceeds analyst price target upside.
J&J Shares Hold Ground Despite 5.5% EPS Guidance Cut
Johnson & Johnson (NYSE:JNJ) closed at $259.24 on Friday, up 0.9%, despite a 5.5% cut to its 2026 adjusted EPS guidance. Investors appear to view the dilution as pipeline investment.
Pfizer Stock Rises 7% as Non-COVID Drugs Offset Pandemic Revenue Decline
Pfizer shares rose 7% last week, driven by strong performance from Eliquis and other key drugs that offset declining COVID product sales.
Pfizer Stock Rises as Core Drug Growth Offsets COVID Decline
Pfizer (PFE) shares rose 0.9% after Q2 results beat estimates, with non-COVID drug growth offsetting a steep decline in COVID product sales.
Pfizer Stock Rises as Non-COVID Drugs Offset Pandemic Revenue Slump
Pfizer's Q2 beat estimates as four growth brands offset COVID revenue declines. Shares rose 1.48% premarket.
AZN-BMY Merger Talks: A $455B Pharma Mega-Deal in the Making?
AstraZeneca and Bristol Myers Squibb are reportedly in merger talks, which could create a $455 billion pharmaceutical giant. Reuters has not confirmed the report.
Tech Gains Mask Narrow Market as Jobs Report Looms
Stocks closed higher this week, but tech-led gains masked a narrow rally. Investors now await the July jobs report, which could influence Fed rate hike expectations.
Gossamer Bio Stock Jumps on FDA Filing Update, but Cash and Dilution Risks Remain
Gossamer Bio shares surged after an FDA filing update, but cash concerns and potential dilution continue to weigh on the stock.
Pfizer Gains 3.6% as Dividend Yield Attracts Income Investors
Pfizer (PFE) shares climbed 3.6% as its 6.9% dividend yield attracted income-focused investors, despite unchanged analyst estimates and a slight earnings forecast cut.
Agenus Shares Surge 83% on $340M Financing for Key Colon Cancer Trial
Agenus shares surged 83% on news of up to $340M financing for a pivotal colon cancer trial, but three-quarters of that amount hinges on investor warrants.
Pfizer's 7% Dividend Yield Attracts Income Seekers Amid Market Turmoil
Pfizer (PFE) added 1.28% in post-market trading Monday, outperforming the broader market as investors rotated into defensive stocks amid geopolitical tensions and a tech selloff.
Agenus Stock Surges 59% on $340 Million Funding Deal
Agenus (AGEN) shares jumped 59% premarket on a $340 million financing deal, though full exercise of warrants could nearly triple the share count. The funds support a strategic pivot to a major colon cancer trial.
Pfizer Gains FDA Nod for Padcev Combo, Yet Stock Remains Flat
Pfizer's Padcev/Keytruda combo gets FDA approval for bladder cancer, but the stock dipped 0.33%. Wall Street remains cautious about revenue impact.
Dividend ETFs Face Headwinds as Oil, Rates, and AI Shifts Fragment Markets
Dividend ETFs are under pressure as oil prices surge and Treasury yields climb, with SCHD and VYM trailing the S&P 500. Investors weigh concentration risks, sector exposure, and payout stability.
Pfizer's Dividend Sustainability in Focus After HSBC Downgrade
Pfizer shares slid after HSBC downgraded the stock, turning investor attention to the sustainability of its 7.3% dividend yield amid a payout ratio near 60% of adjusted EPS guidance.
Pfizer's 7% Yield Attracts Income Seekers as Pharma Sector Stalls
Pfizer shares edged up 1.84% to $24.32, offering a 7.07% yield, but the stock has declined 14.12% over the past three months amid a sluggish pharmaceutical sector.